The Work of Doctor Clay Siegail

This includes information around a Chairman, President and CEO of Seattle Genetics Clay Siegail. There was a surprising statistic about the widespread presence of Cancer that came from the National Cancer Institute, almost forty percent of women and men can anticipate to find a diagnosis of cancer in their lifetime.

There is a focus on a finding for treatment of cancer through research drugs. This is keeping the company on the edge of a lead for medical science for patients that require it the most. An important cancer drug available is called (ADC) antibody drug conjugates. This could give better future possibilities for patients of cancer. It is considered by the company to be an important component of the cancer paradigm treatment. This is because of the potency and stability targeted in specific conditions.

The most popular kind of cancer in men is prostate. Also, in women it’s breast cancer, these types remain the most popular types which affect thousands of Americans every year. It seems that an increase in cancers of skin and colon, and other kinds have led researchers to view new methods for the cancer treatment and diagnosis.

But, in the world of genetic tests there has been a reduced cost of genetic sequence and an increased speed seen. A lot of current research has been found on taking out the DNA code to diagnose cancer accurately and promptly. Then the information is used to make targeted disease treatments.

Now some general information about Dr. Clay Siegal. The Doctor found this company in 1998. In education, the Doctor has received a B.S in Zoology at the University of Maryland and a Ph.D. in Genetics from George Washington University. Also, he holds fifteen patents and authors over 70 publications.

The Doctor has led Seattle Genetics in activities raising capital. This has secured over $674 million in private and public financings. For example, the company in 2001 preformed an initial public offering. The company has built a pipeline of diversity of cancer therapies that are antibody-based. One of them was ADCETRIS that has been granted approval by the FDA.